Clinical trials: Hepatobiliary Disorders
Chronic Hepatitis b, Non-Alcoholic Fatty Liver Disease
Comparison of Hepatus and FibroScan for Evaluation of Fibrosis and Steatosis
Totals of 400 chronic hepatitis B or non-alcoholic fatty liver disease (NAFLD) patients with or without cirrhosis will be enrolled.
- Trial name
- NCT05786963
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Friendship Hospital
NASH With Fibrosis
Non-alcoholic Steatohepatitis Registry Platform Study
This is a multi-center, prospective, observational registry platform study aimed at describing the clinical characteristics and diagnosis and treatment patterns of Chinese patients with nonalcoholic steatohepatitis (NASH) with…
- Trial name
- NCT06123858
- Where
- 16 sites in China
- Volunteers
- 1,122 people
- Sponsor
- AstraZeneca
Fatty Liver, Nonalcoholic
Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease
The aim of the current study is to evaluate the safety and efficay of cilostazol in treatment of patients with fatty liver disease. Several previous reports have shown that cilostazol ameliorates lipid imbalances in NAFLD.
- Trial name
- NCT04761848
- Testing
- Cilostazol 50 MG
- Where
- Egypt
- Sponsor
- Sadat City University
Fatty Liver
Resveratrol in Patients With Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) and fatty liver hepatitis (NASH) are very common in the Western world and strongly associated with obesity. No known effective treatment is known.
- Trial name
- LIRMOI3 (NCT01464801)
- Testing
- Resveratrol
- Where
- Denmark
- Volunteers
- 28 people
- Sponsor
- University of Aarhus
Non-alcoholic Fatty Liver Disease
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
The objective of this study is to provide clinical data to support the effectiveness of a mixture of ingredients of natural origin, suitably selected and packaged, in the protection from liver damage, in subjects with NAFLD.
- Trial name
- NUTRAFAST (NCT02369536)
- Testing
- nutraceutical mixture
- Where
- Italy
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
Autoimmune Liver Disease, Primary Sclerosing Cholangitis
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents.
- Conditions
- Autoimmune Liver Disease, Primary Sclerosing Cholangitis, Autoimmune Hepatitis
- Trial name
- NCT03175471
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Nonalcoholic Steatohepatitis (NASH)
A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
An Open-Label Part was added: This part will enroll in selected sites which are less affected by the COVID-19 pandemic. 150 subjects with NASH and fibrosis confirmed by liver histology (F1-F3) will be randomized into 3 groups…
- Trial name
- ARMOR (NCT04104321)
- Testing
- Aramchol free acid
- Where
- 2 sites in United States
- Volunteers
- 157 people
- Sponsor
- Galmed Research and Development, Ltd.
Non-alcoholic Fatty Liver Disease
Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis.
- Trial name
- NCT02875392
- Testing
- 275mg Oligo Fucoidan + 275mg HS Fucoxanthin
- Where
- Taiwan
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University WanFang Hospital
NASH, NAFLD
Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease
The prevalence of Metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe form, Metabolic dysfunction-associated steatohepatitis (MASH), is high and they are increasingly becoming major causes of…
- Trial name
- CALIBRE (NCT06879236)
- Where
- Italy
- Volunteers
- 252 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NAFLD
Evaluate the Efficacy and Safety of LivPhcD Capsules in the NAFLD Subjects
Non-alcoholic fatty liver disease (also called NAFLD) is a disease in which excessive fat accumulates in the liver of a patient without a history of alcohol abuse.
- Trial name
- NCT05930093
- Testing
- 2 cap.LivPhcD/per day, 4 cap.LivPhcD/per day, 6 cap.LivPhcD/per day
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- TCM Biotech International Corp.
Visceral Obesity, Non-Alcoholic Fatty Liver Disease
Effect of a Multi-ingredient on Visceral Adiposity and Non-alcoholic Fatty Liver Disease in Individuals With Abdominal Obesity
The aim of this study is to validate the efficacy of specific combination of different natural histidine-related amino acids in the reduction of visceral fat and liver steatosis, as well their associated comorbidities, in…
- Trial name
- FATHIS (NCT05807204)
- Testing
- Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Fundació Eurecat
Pancreatic Cancer, Esophageal Cancer
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
The purpose of this research study is to addresses the challenge of managing the unique perioperative needs of older cancer patients undergoing surgical resection.
- Conditions
- Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Rectal Cancer
- Trial name
- NCT02810652
- Testing
- Usual Care, Perioperative Geriatrics Intervention
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Massachusetts General Hospital
Diabetes Complications, Fatty Liver
Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common complications of type 2 diabetes and leading causes of liver disease in the US and Europe.
- Trial name
- NCT00529204
- Testing
- exenatide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, Davis
Rheumatoid Arthritis, Ankylosing Spondylitis
PatientSpot Formerly Known as ArthritisPower
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout
- Trial name
- NCT03840928
- Where
- United States
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Global Healthy Living Foundation
Chronic Hepatitis C
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
This study aims to evaluate whether an investigational monoclonal antibody, CT-011, is safe to give and if it helps patients with hepatitis C virus (HCV).
- Trial name
- NCT00962936
- Testing
- CT-011
- Where
- Israel
- Volunteers
- 13 people
- Sponsor
- CureTech Ltd
Thrombocytopenia; Drugs, Chronic Liver Disease
Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure
In this study, investigators aimed to evaluate the efficacy of Avatrombopag in thrombocytopenic patients with chronic liver disease undergoing an elective invasive procedure through a prospective, non-randomized controlled…
- Trial name
- NCT04915287
- Testing
- Avatrombopag maleate, Platelet transfusion, Medicine
- Where
- China
- Volunteers
- 476 people
- Sponsor
- Chinese PLA General Hospital
Blood Disease, Hepatitis, Viral, Human
Delta Hepatitis and Liver Disease in Hemophiliacs
To determine the prevalence of hepatitis delta virus (HDV) in a large cohort of hemophiliacs and to elucidate the role of HDV in the development and progression of liver disease in this population.
- Conditions
- Blood Disease, Hepatitis, Viral, Human, Hemophilia A, Liver Diseases
- Trial name
- NCT00005304
- Sponsor
- Baylor College of Medicine
Hepatitis, Liver Cirrhosis
Evaluation the Growth Factors(IGF-1,IGFBP-3and HGH)in Patients With Chronic Liver Disease
BACKGROUND The insulin-like growth factor system (IGFs) plays an important role in cell growth and differentiation. Nevertheless, the roles played by insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding…
- Conditions
- Hepatitis, Liver Cirrhosis, Hepatocellular Carcinoma
- Trial name
- NCT00679692
- Where
- Taiwan
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
HEPATITIS C (HCV)
North Jersey Community Research Initiative (NJCRI) Study on Transgender Liver Health
Primary Objective: Assess disparities in liver health outcomes among transgender individuals on GAHT by evaluating liver function markers (transaminases, bilirubin levels, etc), as well as liver elasticity and presence of liver…
- Trial name
- NCT07746999
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Corey DeStefano
NAFLD
The Effect of Consecutive Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic fatty liver disease (NAFLD) is a disease of alarmingly increasing prevalence, linked to metabolic, cardiovascular and malignant morbidity and without any officially approved treatment.
- Trial name
- NAFTx (NCT04465032)
- Testing
- Gut microbiome transplantation
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Leiden University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.